A detailed history of Rhumbline Advisers transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 133,114 shares of AVIR stock, worth $424,633. This represents 0.0% of its overall portfolio holdings.

Number of Shares
133,114
Previous 137,598 3.26%
Holding current value
$424,633
Previous $455,000 2.2%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.17 - $4.02 $14,214 - $18,025
-4,484 Reduced 3.26%
133,114 $445,000
Q2 2024

Aug 01, 2024

SELL
$3.31 - $4.04 $14,246 - $17,388
-4,304 Reduced 3.03%
137,598 $455,000
Q1 2024

May 09, 2024

SELL
$3.09 - $4.56 $16,111 - $23,775
-5,214 Reduced 3.54%
141,902 $573,000
Q4 2023

Feb 08, 2024

BUY
$2.8 - $3.35 $35,862 - $42,906
12,808 Added 9.54%
147,116 $448,000
Q3 2023

Nov 09, 2023

SELL
$3.0 - $3.79 $20,241 - $25,571
-6,747 Reduced 4.78%
134,308 $402,000
Q2 2023

Aug 08, 2023

BUY
$3.21 - $5.06 $55,751 - $87,882
17,368 Added 14.04%
141,055 $527,000
Q1 2023

May 11, 2023

BUY
$3.0 - $4.97 $16,782 - $27,802
5,594 Added 4.74%
123,687 $414,000
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.17 $8,608 - $12,210
1,979 Added 1.7%
118,093 $568,000
Q3 2022

Nov 10, 2022

BUY
$5.49 - $8.79 $35,146 - $56,273
6,402 Added 5.84%
116,114 $661,000
Q2 2022

Aug 11, 2022

BUY
$5.33 - $8.18 $146,441 - $224,745
27,475 Added 33.41%
109,712 $779,000
Q1 2022

May 12, 2022

SELL
$5.5 - $9.19 $22,011 - $36,778
-4,002 Reduced 4.64%
82,237 $594,000
Q4 2021

Feb 10, 2022

BUY
$7.67 - $44.59 $4,195 - $24,390
547 Added 0.64%
86,239 $771,000
Q3 2021

Nov 12, 2021

BUY
$21.33 - $35.06 $76,702 - $126,075
3,596 Added 4.38%
85,692 $3 Million
Q2 2021

Aug 05, 2021

BUY
$19.22 - $59.08 $1.25 Million - $3.84 Million
64,933 Added 378.33%
82,096 $1.76 Million
Q1 2021

May 06, 2021

BUY
$41.42 - $88.44 $192,478 - $410,980
4,647 Added 37.13%
17,163 $1.06 Million
Q4 2020

Feb 10, 2021

BUY
$26.36 - $41.78 $329,921 - $522,918
12,516 New
12,516 $523,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.